FDA approves another indication for Keytruda, this time in the adjuvant NSCLC setting
Merck’s blockbuster cancer treatment Keytruda has been handed another indication by the FDA.
The US regulator announced on Thursday that it …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
